Bispecific T cell activating antigen binding molecules

Patent metadata

Field	Value
Publication number	US-10155815-B2
Application number	US-201414188486-A
Country	US
Kind code	B2
Filing date	Feb 24, 2014
Priority date	Feb 26, 2013
Publication date	Dec 18, 2018
Grant date	Dec 18, 2018

Abstract

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

First claim

The invention claimed is:

1. A T cell activating bispecific antigen-binding molecule comprising:
(i) a first antigen-binding moiety which is a Fab molecule capable of specific binding to CD3, the first antigen-binding moiety comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 7, wherein the first antigen-binding moiety is a crossover Fab molecule, wherein either the variable or the constant regions of the Fab light chain and the Fab heavy chain are exchanged;
(ii) a second antigen-binding moiety and a third antigen-binding moiety, each of which is a Fab molecule capable of specific binding to CEA, the second and third antigen-binding moieties each comprising the heavy chain complementarity determining region (CDR) 1 of SEQ ID NO: 24, the heavy chain CDR 2 of SEQ ID NO: 25, the heavy chain CDR 3 of SEQ ID NO: 26, the light chain CDR 1 of SEQ ID NO: 28, the light chain CDR 2 of SEQ ID NO: 29, and the light chain CDR 3 of SEQ ID NO: 30; and
(iii) an Fc domain comprising a first subunit and a second subunit capable of stable association, wherein the second antigen-binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding moiety, and the first antigen-binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, and wherein the third antigen-binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain.

2. The T cell activating bispecific antigen-binding molecule of claim 1 , wherein the Fc domain is an IgG Fc domain.

3. The T cell activating bispecific antigen-binding molecule of claim 1 , wherein the Fc domain is a human Fc domain.

4. The T cell activating bispecific antigen-binding molecule of claim 1 , wherein the Fc domain comprises a modification promoting the association of the first and the second subunit of the Fc domain.

5. The T cell activating bispecific antigen-binding molecule of claim 4 , wherein in the CH3 domain of the first subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the CH3 domain of the first subunit which is positionable in a cavity within the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the CH3 domain of the second subunit within which the protuberance within the CH3 domain of the first subunit is positionable.

6. The T cell activating bispecific antigen-binding molecule of claim 1 , wherein the Fc domain exhibits reduced binding affinity to an Fc receptor and/or reduced effector function, as compared to a native IgG 1 Fc domain.

7. The T cell activating bispecific antigen-binding molecule of claim 1 , wherein the Fc domain comprises one or more amino acid substitutions that reduce binding to an Fc receptor and/or reduce effector function.

8. The T cell activating bispecific antigen-binding molecule of claim 7 , wherein the Fc domain is a human IgG1 Fc domain and said one or more amino acid substitutions are at one or more positions selected from the group of L234, L235, and P329 (EU numbering).

9. The T cell activating bispecific antigen-binding molecule of claim 8 , wherein each subunit of the Fc domain comprises three amino acid substitutions that reduce binding to an activating Fc receptor and/or reduce effector function, wherein said amino acid substitutions are L234A, L235A, and P329G.

10. The T cell activating bispecific antigen-binding molecule of claim 6 , wherein the Fc receptor is an Fcγ receptor.

11. The T cell activating bispecific antigen-binding molecule of claim 6 , wherein the effector function is antibody-dependent cell-mediated cytotoxicity (ADCC).

12. The T cell activating bispecific antigen-binding molecule of claim 1 , wherein the second and the third antigen binding moiety each comprise a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 23 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 27.

13. The T cell activating bispecific antigen-binding molecule of claim 1 , wherein the Fc domain is a human IgG 1 Fc domain.

14. The T cell activating bispecific antigen-binding molecule of claim 13 , wherein in the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W), and in the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V) (EU numbering).

15. The T cell activating bispecific antigen-binding molecule of claim 14 , wherein in the second subunit of the Fc domain the threonine residue at position 366 is replaced with a serine residue (T366S), and the leucine residue at position 368 is replaced with an alanine residue (L368A) (EU numbering).

16. The T cell activating bispecific antigen-binding molecule of claim 14 , wherein in the first subunit of the Fc domain the serine residue at position 354 is replaced with a cysteine residue (S354C), and in the second subunit of the Fc domain the tyrosine residue at position 349 is replaced by a cysteine residue (Y349C) (EU numbering).

17. The T cell activating bispecific antigen-binding molecule of claim 13 , wherein each subunit of the Fc domain comprises the amino acid substitutions of L234A, L235A, and P329G (EU numbering).

18. The T cell activating bispecific antigen-binding molecule of claim 1 , wherein the first antigen-binding moiety is a crossover Fab molecule wherein the constant regions of the Fab light chain and the Fab heavy chain are exchanged.

19. The T cell activating bispecific antigen-binding molecule of claim 1 , comprising not more than one antigen-binding moiety capable of specific binding to CD3.

20. A pharmaceutical composition comprising the T cell activating bispecific antigen-binding molecule of claim 1 and a pharmaceutically acceptable carrier.

21. A T cell activating bispecific antigen-binding molecule comprising:
(i) a first antigen-binding moiety which is a Fab molecule capable of specific binding to CD3, the first antigen-binding moiety comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 7, wherein the first antigen-binding moiety is a crossover Fab molecule, wherein either the variable or the constant regions of the Fab light chain and the Fab heavy chain are exchanged;
(ii) a second antigen-binding moiety and a third antigen-binding moiety, each of which is a Fab molecule capable of specific binding to CEA, the second and third antigen-binding moieties each comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 23 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 27; and
(iii) an Fc domain comprising a first subunit and a second subunit capable of stable association, wherein the second antigen-binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding moiety, and the first antigen-binding moiety is fused at the C-terminus of the Fab heavy chain to the N-termi

Assignees

• Roche Glycart Ag

Inventors

• Bacac Marina
• Hofer Thomas
• Hosse Ralf
• Neumann Christiane
• Klein Christian
• Moessner Ekkehard
• Umana Pablo
• Weinzierl Tina

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• C07K16/2809 Primary

  against the T-cell receptor (TcR)-CD3 complex · CPC title